Format

Send to

Choose Destination
Clin Rheumatol. 2017 Nov;36(11):2455-2460. doi: 10.1007/s10067-017-3822-3. Epub 2017 Sep 14.

Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.

Author information

1
Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina. juliademarchireum@gmail.com.
2
Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina.
3
Hospital B. Rivadavia, Buenos Aires, Argentina.
4
Hospital Alemán, Buenos Aires, Argentina.
5
Hospital Privado de Córdoba, Córdoba, Argentina.
6
Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
7
Organización Médica de Investigación (OMI), Buenos Aires, Argentina.
8
Clínica Bessone, Buenos Aires, Argentina.

Abstract

The use of hydroxychloroquine (HCQ) in Primary Sjögren's Syndrome (pSS) has been assessed in different studies over the last years, with conflicting results regarding its efficacy in sicca syndrome and extraglandular manifestations (EGM). The goal of this study was to compare the incidence rate of EGM in pSS patients with and without HCQ therapy.We performed a multicenter retrospective study, including patients with pSS (European classification criteria) with at least 1 year of follow-up. Subjects with concomitant fibromyalgia, autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis were excluded. Demographics and pSS characteristics were recorded. The EGM were defined by EULAR-SS disease activity index (ESSDAI). Patients were divided into two groups according to their use or not of HCQ therapy. We evaluated the use of HCQ and its relationship to EGM. HCQ therapy was defined as the continuous use of the drug for at least 3 months. A descriptive analysis of demographics and pSS characteristics was performed. We compared the incidence of EGM between groups defined by HCQ therapy using chi2 test or Fisher's exact test. A total of 221 patients were included (97.3% women), mean age, 55.7 years (SD 14). Mean age at diagnosis, 48.8 years (SD 15); median disease duration, 60 months (IQR 35-84). One hundred and seventy patients (77%) received HCQ. About half of the patients had at least one EGM during the course of the disease, 20% of them developed an EGM before the onset of the sicca syndrome and 26% simultaneously with dryness symptom. Overall, EGM were less frequent in those on HCQ therapy (36.5% vs 63.5%, p < 0.001). Considering each EGM individually, the following manifestations were more frequent in the non-treated group: arthritis (p < 0.001), fatigue (p < 0.001), purpura (p = 0.01), Raynaud phenomenon (p = 0.003), and hypergammaglobulinemia (p = 0.006). Immunosuppressive treatment was indicated on 28 patients (12.7%), 13 of which were receiving also HCQ. The first reason for those treatments was the presence of arthritis in 12/28 patients (42.8%), and the drug used in all the cases was methotrexate. Only three patients required immunosuppressive therapy with cyclophosphamide, due to the presence of glomerulonephritis, vasculitis, and interstitial lung disease. None of the patients received biologic therapy. The lower incidence of EGM was observed in patients on HCQ therapy supports its efficacy in pSS. However, further large scale prospective studies are needed to confirm these findings.

KEYWORDS:

Extraglandular manifestations; Hydroxychloroquine; Primary Sjögren’s syndrome; Treatment

PMID:
28913747
DOI:
10.1007/s10067-017-3822-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center